Real Life Clinical Effectiveness of Razumab® (World’s First Biosimilar Ranibizumab) in Wet Age-Related Macular Degeneration: A Subgroup Analysis of Pooled Retrospective RE-ENACT Study

Journal Title: International Journal of Ophthalmology & Eye Science (IJOES) - Year 2018, Vol 6, Issue 2

Abstract

Background: This subgroup analysis of RE-ENACT study (retrospective, multicenter, observational pooled study on wet age-related macular degeneration [wet AMD], diabetic macular edema, and retinal vein occlusion) evaluated the effectiveness of Razumab® (world’s first biosimilar ranibizumab by Intas Pharmaceuticals Ltd., India) in Indian patients with wet AMD. Methods: Data of the patients with wet AMD, who were treated with ≥3 injections of Razumab® between January and August 2016, were included. Endpoints were: improvement in best corrected visual acuity (BCVA, measured by logMAR/ Snellen’s chart), decrease in central macular thickness (CMT, measured by Spectral Domain Optical Coherence Tomography), and intraretinal fluid (IRF) and subretinal fluid (SRF) from baseline at Weeks 4, 8 and 12. Result: Medical charts of 194 patients were analysed; 112 (57.73%) were men, 82 (42.27%) were women. Mean ± SE BCVA improved from baseline (0.81 ± 0.03) at Week 4 (0.78 ± 0.03; p=0.13) and attained significance at Weeks 8 (0.66 ± 0.02) and 12 (0.55 ± 0.02; p<0.0001 for both time points); mean ± SE CMT significantly decreased from baseline (393.02 ± 7.32 μm) to Weeks 4 (385.93 ± 7.10 μm; p=0.0041), 8 (332.75 ± 6.10 μm; p<0.0001) and 12 (293.5 ± 4.10 μm; p<0.0001). Proportion of patients with IRF and SRF significantly (P<0.0001) decreased from baseline to Weeks 4, 8 and 12 (59.79% vs. 47.94%, 41.75%, and 31.96%, respectively for IRF; and 82.47% vs. 66.49%, 51.03%, 41.24%, respectively for SRF). No new safety concerns with biosimilar ranibizumab were observed. Conclusion: Razumab® (biosimilar ranibizumab) effectively improved the visual acuity and disease outcomes with no new safety concerns in patients with wet age-related macular degeneration in the real world setting.

Authors and Affiliations

Sharma Shashikant

Keywords

Related Articles

5- Fluorouracil Versus Triamcinolone Injection in the Management of Periocular Scars

Purpose: The purpose of our study was to compare the effects of intralesional 5 Fluorouracil versus Triamcinolone injection for the modulation of periocular scar formation and wound contracture. Methods: Prospective inte...

Posterior Cerebral Artery Infarct with Haemorrhagic Transformation

A 65-year-old female presented with visual disturbances a week following surgical breast biopsy and stopping eliquis. A diagnosis of a perioperative posterior cerebral ischemic stroke with haemorrhagic transformation, in...

A Mechanism for Spontaneous Closure of a Traumatic Macular Hole with Commotio Retinae in a Pediatric Patient

Macular holes can arise from different etiologies and can lead to vision loss. Though various treatments have been proposed, the management of traumatic macular holes is not widely standardized. We report on a case of a...

Transconjunctival Lower Lid Blepharoplasty Made Easy by Everting the Eyelid

Purpose: To evaluate the transconjunctival lower lid blepharoplasty using a Desmarres lid retractor to evert the eyelid. Design: Prospective study. Methods: Twenty-one cases of inferior blepharoplasty in 11 patients, per...

Daylight For Healthy Indoor Environment And Energy Benefits

Daylight For Healthy Indoor Environment And Energy Benefits

Download PDF file
  • EP ID EP533030
  • DOI 10.19070/2332-290X-1800074
  • Views 43
  • Downloads 0

How To Cite

Sharma Shashikant (2018). Real Life Clinical Effectiveness of Razumab® (World’s First Biosimilar Ranibizumab) in Wet Age-Related Macular Degeneration: A Subgroup Analysis of Pooled Retrospective RE-ENACT Study. International Journal of Ophthalmology & Eye Science (IJOES), 6(2), 368-373. https://europub.co.uk/articles/-A-533030